Moehler T - Search Results

1

Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.

Schmidt-Wolf IG, Glasmacher A, Hahn-Ast C, Jüttner A, Schnurr T, Cremer F, Moehler T, Goldschmidt H, Busert B, Schubert R, Schwanitz G. Schmidt-Wolf IG, et al. Among authors: moehler t. Cancer Genet Cytogenet. 2006 May;167(1):20-5. doi: 10.1016/j.cancergencyto.2005.10.016. Cancer Genet Cytogenet. 2006. PMID: 16682281

2

[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma].

Moehler TM, Hawighorst H, Neben K, Egerer G, Benner A, Hillengass J, Max R, Ho AD, Goldschmidt H, van Kaick G. Moehler TM, et al. Radiologe. 2000 Aug;40(8):723-30. doi: 10.1007/s001170050802. Radiologe. 2000. PMID: 11006943 Clinical Trial. German.

3

Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging.

Moehler TM, Hawighorst H, Neben K, Egerer G, Hillengass J, Max R, Benner A, Ho AD, van Kaick G, Goldschmidt H. Moehler TM, et al. Int J Cancer. 2001 Sep;93(6):862-8. doi: 10.1002/ijc.1421. Int J Cancer. 2001. PMID: 11519049

4

High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.

Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, Ho AD, Goldschmidt H. Neben K, et al. Among authors: moehler t. Clin Cancer Res. 2001 Sep;7(9):2675-81. Clin Cancer Res. 2001. PMID: 11555579 Clinical Trial.

5

Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion.

Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho AD, Goldschmidt H. Neben K, et al. Among authors: moehler t. Br J Haematol. 2001 Dec;115(3):605-8. doi: 10.1046/j.1365-2141.2001.03142.x. Br J Haematol. 2001. PMID: 11736942 Free article. Clinical Trial.

6

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.

Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD, Goldschmidt H. Moehler TM, et al. Blood. 2001 Dec 15;98(13):3846-8. doi: 10.1182/blood.v98.13.3846. Blood. 2001. PMID: 11739195 Free article.

7

Angiogenesis in hematologic malignancies.

Moehler TM, Neben K, Ho AD, Goldschmidt H. Moehler TM, et al. Ann Hematol. 2001 Dec;80(12):695-705. doi: 10.1007/s00277-001-0398-3. Epub 2001 Nov 14. Ann Hematol. 2001. PMID: 11797109 Review.

8

Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.

Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, Opelz G, Goldschmidt H. Neben K, et al. Blood. 2002 Sep 15;100(6):2263-5. Blood. 2002. PMID: 12200397 Free article. Clinical Trial.

9

Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.

Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H. Neben K, et al. Among authors: moehler t. Clin Cancer Res. 2002 Nov;8(11):3377-82. Clin Cancer Res. 2002. PMID: 12429624 Clinical Trial.

10

Angiogenesis in hematologic malignancies.

Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Moehler TM, et al. Crit Rev Oncol Hematol. 2003 Mar;45(3):227-44. doi: 10.1016/s1040-8428(02)00135-x. Crit Rev Oncol Hematol. 2003. PMID: 12633837 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters